Show simple item record

dc.contributor.authorGärtner, Runeen_US
dc.contributor.authorCronin-Fenton, Deirdreen_US
dc.contributor.authorHundborg, Heidi Hen_US
dc.contributor.authorPedersen, Larsen_US
dc.contributor.authorLash, Timothy Len_US
dc.contributor.authorSørensen, Henrik Toften_US
dc.contributor.authorKroman, Nielsen_US
dc.date.accessioned2012-01-11T22:21:33Z
dc.date.available2012-01-11T22:21:33Z
dc.date.copyright2010en_US
dc.date.issued2010-1-24en_US
dc.identifier.citationGärtner, Rune, Deirdre Cronin-Fenton, Heidi H Hundborg, Lars Pedersen, Timothy L Lash, Henrik Toft Sørensen, Niels Kroman. "Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study" BMC Surgery 10:3. (2010)en_US
dc.identifier.issn1471-2482en_US
dc.identifier.urihttp://hdl.handle.net/2144/3261
dc.description.abstractBACKGROUND. Selective serotonin reuptake inhibitors (SSRI) decrease platelet-function, which suggests that SSRI use may increase the risk of post-surgical bleeding. Few studies have investigated this potential association. METHODS. We conducted a population-based study of the risk of re-operation due to post-surgical bleeding within two weeks of primary surgery among Danish women with primary breast cancer. Patients were categorised according to their use of SSRI: never users, current users (SSRI prescription within 30 days of initial breast cancer surgery), and former users (SSRI prescription more than 30 days before initial breast cancer surgery). We calculated the risk of re-operation due to post-surgical bleeding within 14 days of initial surgery, and the relative risk (RR) of re-operation comparing SSRI users with never users of SSRI adjusting for potential confounders. RESULTS. 389 of 14,464 women (2.7%) were re-operated. 1592 (11%) had a history of SSRI use. Risk of re-operation was 2.6% among never users, 7.0% among current SSRI users, and 2.7% among former users. Current users thus had an increased risk of re-operation due to post-operative bleeding (adjusted relative risk = 2.3; 95% confidence interval (CI) = 1.4, 3.9) compared with never users. There was no increased risk of re-operation associated with former use of SSRI (RR = 0.93, 95% CI = 0.66, 1.3). CONCLUSIONS. Current use of SSRI is associated with an increased risk of re-operation due to bleeding after surgery for breast cancer.en_US
dc.description.sponsorshipRigshospitalet; Danish Cancer Society; Breast Friends; Lundbeck Foundation; Karen Elise Jensen Foundation; Western Danish Research Forum for Health Sciences; Aarhus Universityen_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2010 Gärtner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleUse of Selective Serotonin Reuptake Inhibitors and Risk of Re-Operation Due to Post-Surgical Bleeding in Breast Cancer Patients: A Danish Population-Based Cohort Studyen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1471-2482-10-3en_US
dc.identifier.pubmedid20096133en_US
dc.identifier.pmcid2823600en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2010 Gärtner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2010 Gärtner et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.